Neuronal nicotinic acetylcholine receptor alpha-4 beta-2 (nAChR α4β2) (nAChR α4β2)

The neuronal nicotinic acetylcholine receptor alpha-4 beta-2 (nAChR α4β2) is a pentameric ligand-gated ion channel and the most prevalent nicotinic receptor subtype in the mammalian brain [1, 3]. It is primarily composed of α4 and β2 subunits, which typically assemble into two distinct stoichiometries—(α4)2(β2)3 and (α4)3(β2)2—differing in their sensitivity to agonists and calcium permeability [2, 3]. These receptors are widely distributed across brain regions such as the thalamus, cortex, and hippocampus, where they modulate the release of neurotransmitters like dopamine, glutamate, and GABA [1, 5, 11]. Due to its high affinity for nicotine, the α4β2 subtype is the principal mediator of the reinforcing and addictive properties of tobacco [2, 8]. Clinically, the α4β2 receptor is a major therapeutic target for smoking cessation, with the partial agonist varenicline being the most prominent drug used to reduce cravings and withdrawal symptoms [10]. Beyond addiction, these receptors are implicated in the pathophysiology of Alzheimer's disease, Parkinson's disease, and schizophrenia, where their activation is thought to enhance cognitive performance and provide neuroprotection [1, 5]. Genetic mutations in the CHRNA4 or CHRNB2 genes are also linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) [7]. Other β2-containing subtypes, such as α6β2, also play significant roles in dopaminergic signaling and are being investigated as targets for movement disorders and addiction [7, 11].

Other names

α4β2 nicotinic acetylcholine receptorAlpha-4 beta-2 nicotinic receptorHigh-affinity nicotinic receptorNeuronal nAChR beta-2-containing subtypesCHRNA4/CHRNB2 receptorα2β2 nAChRα3β2 nAChRα6β2 nAChR

Drugs targeting these receptors act as agonists, partial agonists, antagonists, or allosteric modulators to regulate the opening of the pentameric ion channel, thereby controlling the influx of cations (Na+, Ca2+) and the subsequent release of neurotransmitters such as dopamine and glutamate [1, 5, 10]. Chronic exposure to agonists like nicotine also leads to receptor desensitization and upregulation, which are key mechanisms in the development of addiction [12, 13].